Table 2.

Current clinical trials of kinase inhibitor-based therapies for children, adolescents, and adults with Ph-like ALL.

Patient population	Age	Disease status	Inhibitor	Trial
Ph-like with ABL class alterations	≥10 years	relapse	dasatinib	NCT02420717
Ph-like with ABL class alterations	1–30 years	de novo	dasatinib	NCT01406756
Ph-like with ABL class alterations	1–18 years	de novo	dasatinib	NCT03117751
Ph-like with CRLF2/JAK pathway alterations	≥10 years	relapse	ruxolitinib	NCT02420717
Ph-like with CRLF2/JAK pathway alterations	1–21 years	de novo	ruxolitinib	NCT02723994
Ph-like with CRLF2/JAK pathway alterations	1–18 years	de novo	ruxolitinib	NCT03117751